Newer antifungal therapy for emerging fungal pathogens (Q35116244)

6 August 2017

1 reference

title

Newer antifungal therapy for emerging fungal pathogens (English)

1 reference

6 August 2017

2

John R Perfect

1 reference

6 August 2017

1

William J Steinbach

1 reference

6 August 2017

publication date

1 March 2003

1 reference

International Journal of Infectious Diseases

6 August 2017

published in

1 reference

6 August 2017

volume

7

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

5-20

1 reference

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

The new fungal opportunists are coming

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

1 reference

7 January 2021

Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Torulopsis glabrata an emerging yeast pathogen in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

New and emerging yeast pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Antifungal resistance in non- albicans Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Treatment of murine Candida krusei or Candida glabrata infection with L-743,872

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Candida lusitaniae catheter-related sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Taxonomy, biology, and clinical aspects of Fusarium species

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Fusarium solani infection during treatment for acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Treatment of murine fusariosis with SCH 56592

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro activities of four novel triazoles against Scedosporium spp

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Oral terbinafine for treatment of pulmonaryPseudallescheria boydii infection refractory to itraconazole therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Use of voriconazole in treatment of Scedosporium apiospermum infection: case report

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Disseminated phaeohyphomycosis: review of an emerging mycosis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Penicillium marneffei: types and drug susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Infection Caused byPenicillium marneffei: Description of First Natural Infection in Man

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro comparison of terbinafine and itraconazole against Penicillium marneffei

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro antifungal activity of posaconazole against various pathogenic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

AcremoniumSpecies: New Emerging Fungal Opportunists—In Vitro Antifungal Susceptibilities and Review

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Infection due to the fungus Acremonium (cephalosporium)

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Trichosporon species infection in bone marrow transplanted patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro antifungal susceptibilities of Trichosporon species.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Trichosporon inkin endocarditis: short-term evolution and clinical report

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Trichosporon inkin peritonitis during continuous ambulatory peritoneal dialysis with bibliography review

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Disseminated trichosporonosis: Meeting the challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Transient fungemia due to Rhodotorula rubra in a cancer patient: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Sepsis due to Rhodotorula related to use of indwelling central venous catheters

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Microbiological characteristics and susceptibility patterns of strains of Rhodotorula isolated from clinical samples.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Acute invasive sinusitis due to Trichoderma longibrachiatum in a liver and small bowel transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Successful treatment of a brain abscess due to Trichoderma longibrachiatum after surgical resection

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Infection Due toPaecilomyces lilacinus: A Challenging Clinical Identification

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Paecilomyces lilacinus catheter-related fungemia in an immunocompromised pediatric patient

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Morphologic Criteria for the Preliminary Identification ofFusarium, Paecilomyces, andAcremoniumSpecies by Histopathology

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

1 reference

7 January 2021

Zygomycosis in the 1990s in a tertiary-care cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Opportunistic zygomycotic infections. A literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Mucormycosis (zygomycosis): is there news for the clinician?

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Disseminated zygomycosis: report of four cases and review

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990037-3

7 January 2021

10.1016/S1201-9712(03)90037-3

Identifiers

DOI

1 reference

6 August 2017

1 reference